Koning’s Series C fundraise is now available to accredited investors via a leading tech investment website, Revere
Atlanta, GA: Koning Corporation is now live on the investment platform, Revere, which specializes in raising funds for scalable, high-value technology companies.
“We’re excited to bring this opportunity to investors who believe, like we do, in the advancement of women’s health through better breast imaging techniques,” says Koning’s US CEO, Lutao Ning. “We believe that our technology has the potential to significantly lower breast cancer incidents in women around the world.”
“We believe that our technology has the potential to significantly lower breast cancer incidents in women around the world.”
Breast cancer is the number one form of cancer in women worldwide and accounts for 25% of new cancer diagnoses in women around the world. Current breast imaging modalities fall significantly short in being able to identify lesions; about 35% of breast cancers are missed by traditional mammography, and that number goes up to 70% for women with dense breasts.
“Current breast imaging modalities have been lacking in their ability to confidently recognize breast cancer at earlier stages in its development. The Koning Breast CT can find lesions as small as 2mm and calcifications as small as 200 microns without breast compression. These early findings will significantly increase women’s quality of life as they start the treatment process,” says David Georges, Koning’s US President, a veteran in the breast imaging industry.
Among the Koning Breast CT benefits are:
- Real 3D isotropic images
- No compression of the breasts
- Low radiation doses in same range as mammograms
- 10 second exposures
Koning’s series C fundraise will enable the global expansion of the company, allowing more women to receive suitable exams. Koning is raising $60-80M in equity and $10M in debt to fund the growth of Koning. $45M will go to finance market growth for the current products in China and US (working capital, channel development, clinical marketing), $20M to develop a smaller, lower cost device, covering a more expansive screening market, and $15M to add to the team to accelerate growth and develop service capabilities.
About Koning: Koning is a global HealthTech company that focuses on improving the breast imaging industry with its patented Koning Breast CT (KBCT). Koning’s vision is to create a revolution in medical imaging through advanced computed tomography technology and dramatically improve the way clinicians visualize and evaluate breast tissue. The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide.
Create a profile on Reverevc.com to find more information about the offering.